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Inborn errors of immunity (IEI) are a genetically heterogeneous group of disorders with
a broad clinical spectrum. Identiﬁcation of molecular and functional bases of these
l Mosaic and germline
disorders is important for diagnosis, treatment, and an understanding of the human
gain-of-function
immune response. We identiﬁed 6 unrelated males with neutropenia, infections, lymvariants in TLR8 cause
neutropenia, antibody
phoproliferation, humoral immune defects, and in some cases bone marrow failure asdeﬁciency,
sociated with 3 different variants in the X-linked gene TLR8, encoding the endosomal
lymphoproliferation,
Toll-like receptor 8 (TLR8). Interestingly, 5 patients had somatic variants in TLR8 with
and bone marrow
failure.
<30% mosaicism, suggesting a dominant mechanism responsible for the clinical phenotype. Mosaicism was also detected in skin-derived ﬁbroblasts in 3 patients, demonl TLR8 gain of function
strating
that mutations were not limited to the hematopoietic compartment. All patients
leads to an
inﬂammatory
had refractory chronic neutropenia, and 3 patients underwent allogeneic hematopoietic
environment with
cell transplantation. All variants conferred gain of function to TLR8 protein, and immune
activated T cells and
phenotyping demonstrated a proinﬂammatory phenotype with activated T cells and
abnormalities in B-cell
elevated serum cytokines associated with impaired B-cell maturation. Differentiation of
differentiation.
myeloid cells from patient-derived induced pluripotent stem cells demonstrated increased responsiveness to TLR8. Together, these ﬁndings demonstrate that gain-of-function variants in TLR8 lead to
a novel childhood-onset IEI with lymphoproliferation, neutropenia, infectious susceptibility, B- and T-cell defects,
and in some cases, bone marrow failure. Somatic mosaicism is a prominent molecular mechanism of this new disease.
(Blood. 2021;137(18):2450-2462)
KEY POINTS

Introduction
Inborn errors of immunity (IEI) are a heterogeneous group of
genetic disorders affecting the immune system with multiple
clinical manifestations, including infection, autoimmunity,
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autoinﬂammation, bone marrow failure, malignancy, and
atopy.1,2 Genomic investigation of rare patients with IEI has
revealed a spectrum of genetic inheritance and mechanisms of
disease, including loss-of-function and gain-of-function variants,
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We identiﬁed 6 unrelated males with severe infections, neutropenia, humoral abnormalities, and bone marrow failure
consistent with an IEI. Sequencing of peripheral blood DNA
samples identiﬁed novel missense variants in the TLR8 gene,
with 5 patients having genetic mosaicism. TLR8 is located on the
short arm of chromosome X (Xp22.2) and encodes Toll-like receptor protein 8 (TLR8), an endosomal receptor that senses
microbial single-stranded RNA degradation products and serves
to alert the immune response to the presence of viral and
bacterial infection.9,10 TLR8 is primarily expressed by neutrophils
and monocytes. We investigated the mechanism whereby
identiﬁed variants altered the function of the encoded TLR8
protein and the immune response associated with the clinical
phenotype of patients. Findings identiﬁed increased activity of
TLR8 and downstream inﬂammatory signals associated with
human disease.

Methods
Patients and genetic testing
Written and informed consent was obtained for all participants at
Washington University or the National Institutes of Health. Some
patients were identiﬁed through GeneMatcher.11 These studies
were approved by the institutional review boards of the authors’
institutions. Exome sequencing was performed using wholeblood DNA as a research or clinical test. To conﬁrm genetic
variants and determine allele frequency, droplet digital polymerase chain reaction (ddPCR) (Bio-Rad) was performed with
DNA and/or complementary DNA (cDNA) samples from the
indicated tissue. ddPCR included ddPCR SuperMix for Probes
(no dUTP) (Bio-Rad), reference probe (HEX dye), and probes
speciﬁc for TLR8 c.1295C.T or TLR8 c.1482C.A variants (FAM
dyes, custom design, Bio-Rad), nuclease-free water with 25 ng
DNA or cDNA. All ddPCR assays were analyzed using the QX200
Droplet reader and Quantasoft software version 1.7.4.

Flow cytometry
Immunophenotyping of peripheral blood mononuclear cells
(PBMCs) and analysis of phosphorylated p65 Ser536 (NF-kB)
were performed using standard ﬂow cytometry–based assays.
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Detailed methodology is provided in supplemental Methods
(available on the Blood Web site).

Serum cytokine analysis
Serum cytokines were measured using a multianalyte (13-plex)
(Luminex assay kit; R&D Systems, Minneapolis, MN) by the
Center for Human Immunology and Immunotherapy Programs at
Washington University. Analytes assayed included tumor necrosis factor a (TNF-a), interleukin-18 (IL-18), interferon-g (IFN-g),
BAFF, sIL2Ra, IL-12/23p40, CXCL10, IL-10, IL-6, IL-8, IL-17,
IL1-b, and MCP-1. IL-18 binding protein levels were measured
by a previously deﬁned method.12 Levels of soluble forms of Fas
ligand were quantitated by enzyme-linked immunosorbent assay
(RayBiotech, Norcross, GA).

Transfection studies in TLR8-deﬁcient NF-kB
reporter cell line
Expression plasmids with P432L, F494L, G572D, and D543A
were generated as described in supplemental Methods. Human
HEK Blue Null1 NF-kB reporter cells (InvivoGen), which lack
expression of TLR7 and TLR8, were cultured in Dulbecco’s
modiﬁed Eagle medium supplemented with 10% fetal bovine
serum, normocin (50 mg/mL), blasticidin (10 mg/mL), and Zeocin
(100 mg/mL) (InvivoGen). NF-kB transcriptional activity was
measured by quantifying secreted alkaline phosphatase (SEAP)
by QUANTI-BLUE assay (InvivoGen) in reporter cells transiently
transfected with wild-type (WT) or mutant TLR8 following
stimulation. TLR ligands/agonists used in these studies included
TL8-506 (TLR8 agonist), CLO75 (TLR8/TLR7 agonist), R848
(resiquimod, a TLR7/TLR8 agonist), or CL264 (TLR7 agonist) (all
from InvivoGen). Speciﬁcity of TL8-506 for TLR8 was demonstrated in HEK cells expressing human TLR7, which did not
respond to TL8-506 stimulation (supplemental Figure 2B).
Similarly, cells expressing TLR8 but lacking TLR7 did not respond
to stimulation with CL264 (supplemental Figure 2F). For transfection experiments, brieﬂy, 500 ng (or indicated concentration)
WT or mutant TLR8 plasmid was transiently transfected into
reporter cells (Lipofectamine; Thermo Fisher Scientiﬁc, Waltham,
MA), and 48 hours after transfection, cells were stimulated with
the indicated doses of TLR agonist followed by quantiﬁcation of
SEAP in the supernatant as a readout of NF-kB activity. Fold
change in SEAP activity was calculated by normalizing data to
untransfected wells without TLR8 stimulation. Statistical analysis
was performed by 1-way analysis of variance (ANOVA) using
GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA), where a
P value , .05 was considered signiﬁcant.

Fibroblast and iPSC line generation
Skin-punch biopsies were obtained from patients P1, P2, P3, and
P5 after written informed consent and approval from local institutional review boards at Washington University, Nemours
Alfred I. DuPont Hospital for Children, or Vanderbilt University.
Primary ﬁbroblasts lines from patients were generated by the
Genome Engineering and iPSC Center at Washington University
in St. Louis. Fibroblasts from 2 patients (P2 and P3) were
reprogrammed to induced pluripotent stem cells (iPSCs) by the
Genome Engineering and iPSC Center using the Cytotune 2.0
reprogramming kit (Thermo Fisher Scientiﬁc). Karyotype
(G-banding) was performed and conﬁrmed 46XY karyotype. The
STEMdiff Hematopoietic Kit (05310, STEMCELL Technologies,
Inc.) was used to differentiate iPSCs into CD341 hematopoietic
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sometimes in the same gene with overlapping or divergent
phenotypes.3-5 While most IEIs are associated with germline
defects, postzygotic mutational events leading to somatic mosaicism can also cause disease; for example, somatic mutation in
hematopoietic stem cells can cause autoimmune lymphoproliferative syndrome.6 The overall number of patients with IEIs due
to postzygotic somatic mosaicism was thought to be relatively
low based on rare case reports. However, recent investigation
using targeted sequencing of 128 families suspected to have
speciﬁc IEIs but without an identiﬁed germline variant found that
;15% of patients had mosaic variants in the known targeted
IEI genes.7 The recent identiﬁcation of somatic mutations in
UBA1 in the hematopoietic cells of men with adult-onset
autoinﬂammatory disease highlights the importance of investigating nongermline genetic variants in IEIs.8 However,
somatic mosaicism is generally overlooked as a cause of IEI and
monogenic disease, particularly with regards to disease discovery. The reasons for this may include challenges in detecting
low-frequency variants and the need to perform genetic testing
on the tissue or cell type carrying the variant.

progenitor cells (HPCs). Detailed methodology is provided in
supplemental Methods.

Generation of iPSCs or modiﬁed CD34-derived
neutrophils and macrophages

Additional methods in online supplement
Additional detailed methodology for protein modeling, protein
expression by western analysis, mass cytometry, and IFN signature studies may be found in supplemental Methods.

Results
Clinical phenotype
All patients (P1-P6) presented with infections leading to diagnosis of neutropenia (Table 1). Clinical case summaries for
each patient may be found in supplemental Methods. Two
patients presented in their ﬁrst year of life (P2 and P6). One
patient (P5) had a history of refractory immune thrombocytopenia and splenomegaly at 5 years of age prior to onset of
neutropenia at age 14 years. Absolute neutrophil counts were
0 or very low at diagnosis (range, 0-284 cells/mL; supplemental
Table 1). All patients had evidence of lymphoproliferation, including lymphadenopathy and/or splenomegaly (Table 1 and
Figure 1A). Two patients had positive antineutrophil antibodies
(supplemental Table 2).
With the exception of P1, who responded to G-CSF therapy and
prednisolone, patients had a poor response to therapeutic or
high doses of G-CSF. Five patients received immunoglobulin
replacement therapy due to low serum immunoglobulin G (IgG),
recurrent infections, and/or low B-cell numbers (Table 1). All
patients received immunosuppressive therapies that included
corticosteroids. Other medications used in .1 patient included
sirolimus and rituximab (clinical case summaries, supplemental
Methods). Bone marrow biopsy ﬁndings varied and included
hypocellularity and lymphohistiocytic or lymphoid aggregates
(Table 1 and Figure 1B-C; supplemental Table 1). A T-cell
clonality test was performed on the bone marrow of 4 patients, and 2 patients had oligoclonality with dominant T-cell
clones in the marrow by T-cell receptor g rearrangement studies
(P1 and P4; Table 1). Three patients (P2, P4, and P5) underwent
hematopoietic cell transplantation (HCT). P2 had bone marrow
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Genetic investigation
Exome sequencing identiﬁed TLR8 gene variants in all patients,
either on initial review or by targeted review of the TLR8 gene
evaluating for low-level mosaicism (Figure 1D). Five patients
(P1-P5) had mosaic TLR8 variants; 4 patients (P1, P2, P4, and P5)
shared the same variant (c.1295 C.T; p.P432L), while the ﬁfth
patient (P3) harbored a different mosaic variant (c.1482 C.A,
p.F494L). The ﬁnal patient (P6) had a de novo germline hemizygous variant in TLR8 (c.1715 G.A, p.G572D). None of the
variants were present in the gnomAD database,14 and all were
predicted to be deleterious by Combined Annotation Dependent Depletion (CADD) score (supplemental Table 3). No
other known disease-causing variants relevant to clinical phenotypes were identiﬁed. To determine the frequency of mosaicism and its origin, ddPCR was performed using DNA and cDNA
from different cell lineages and tissues including whole blood,
PBMCs, puriﬁed immune subsets, saliva and/or skin ﬁbroblast
lines in patients with mosaic variants (Figure 1E-F). All patients
had ,30% mosaicism, with similar allelic frequencies across
different cell types, suggesting the mutational event may have
occurred at an early stage of embryonic development. One
patient (P5) did not carry the mutated allele in a skin ﬁbroblast
line. Analysis of lung tissue of P2 post-HCT at a time when he had
100% donor chimerism revealed the presence of the variant in
the DNA, but not RNA (not shown), consistent with the presence
of genetic mosaicism in lung tissue rather than the presence of
donor immune cells expressing TLR8 transcript.

Functional consequences of TLR8 variants
Monocytes and neutrophils from patients expressed TLR8
protein (Figure 1G). Following ligand binding, TLR8 signaling
activates NF-kB to upregulate a proinﬂammatory transcriptional signal. Stimulation of peripheral blood monocytes with
a low dose of the TLR8 agonist TL8-506 led to the activation
of a small percentage of monocytes (5% to 6%) in patients
with mosaic variants, as measured by phosphorylated p65
(NF-kB) (Figure 1H), suggesting that the observed TLR8
variants may lower the activation threshold to ligand in
primary cells.
Based on mosaicism conferring disease and enhanced activation
of patient cells, we hypothesized that the variants may confer
increased function to the encoded protein. The TLR8 dimer
undergoes a rigid body rotational and hinge motion upon activation (supplemental Figure 2A).15 Residues affected by the
mosaic variants, P432 and F494, contact each other in one
monomer and, after TLR8 activation, come into close contact
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To differentiate neutrophils, CRISPR-modiﬁed CD34s (details for
generation in supplemental Methods) or iPSC-derived CD34s
were maintained in STEMspan media containing stem cell factor
(100 ng/mL, Stem Cell Technologies) and granulocyte colony
stimulating factor (G-CSF; 10 ng/mL, R&D Systems) and were
differentiated by a slight modiﬁcation of a previously described
protocol.13 Cells were pelleted by centrifugation on day 14,
washed in phosphate-buffered saline, and stained with CD45,
CD66b (BD Optibuild) for the deﬁning neutrophil population
(CD451/CD66b1) and used for ﬂuorescence-activated cell
sorting analysis. Neutrophil differentiation was further conﬁrmed
by hematoxylin and eosin (H&E) staining following cytospin
centrifugation on slides at 500 rpm for 8 minutes (Thermo Fisher
Scientiﬁc). Macrophages were differentiated from iPSC-derived
CD34s with Myeloid Expansion Supplement II (Stem Cell
Technologies). Macrophage differentiation was conﬁrmed
on day 14 by ﬂow cytometry as CD451CD141 (BD Biosciences)
and by H&E staining.

ﬁndings of absent neutrophils with normal myeloblasts and a
prolonged period (.9 months) of absent peripheral blood
neutrophils prior to allogeneic HCT from a mismatched unrelated donor. He failed to engraft with his ﬁrst transplant and
was retransplanted several months later but died at day 1172
due to renal failure and vasoplegia (clinical case summaries,
supplemental Methods). P4 was diagnosed with evolving T-cell
large granular lymphocytic (T-LGL) leukemia and underwent
haploidentical donor HCT, subsequently requiring donor T-cell
infusions due to relapse of neutropenia with loss of donor chimerism. P5 had a hypocellular bone marrow with leukopenia and
thrombocytopenia refractory to treatment prior to a matched
sibling HCT. P6 died at 8 years of age due to overwhelming
fungal infections and bone marrow failure.

blood® 6 MAY 2021 | VOLUME 137, NUMBER 18

7y

P3

9 mo
Dec 8 y

P6

p.G527D (germline)

p.P432L (17%)

p.P432L (26%)

p.F494L (8%)

p.P432L (18%)

p.P432L (14%)

TLR8 variant
(frequency in
blood
if mosaic)
Neutrophils, RBCs,
platelets, B cells

Cytopenias

Infection: otitis media,
fungal infections

ITP (age 5 y) infections
(age 16 y)

Infection: Nocardia

Infection: lymphadenitis

HSM, low IgG

HSM, liver with
hemophagocytosis, low IgG

Other major features

HSM, low IgG

Neutrophils, RBCs,
platelets

HSM, lymphadenopathy, low IgG

Current status

Agranulocytosis, oligoclonal
CD81 population (Vb1 CD81)

Hypocellular with myeloid
hypoplasia, lymphohistocytic
aggregates, expanded TCRg/d
T-cell population

Agranulocytosis, normal
myeloblasts, normocellular

Hypocellular with myeloid
hypoplasia and ﬁbrosis

Died due to infection

Alive 100 d post MRD HST

Alive .3 y following
haplo-identical HCT

Stable on G-CSF

Died following MMURD
(9/10) 3 2

Stable on G-CSF and
Well organized lymphoid
corticosteroids
aggregates, normocellular, T-cell
clonality (Vg10 Jg1/2, 66%)

Bone marrow

Hypocellular with myeloid
Neutrophils, platelets Splenomegaly, lymphadenopathy,
hypoplasia, T-cell predominant
recurrent GI inﬂammation/infection,
lymphohistiocytic aggregates
type I DM

Neutrophils, RBCs,
Platelets, B cells

Neutrophils, platelets HSM, low IgG

Infection: Pneumonia and Neutrophils, RBCs
otitis media

Infection: Clostridium
septicum bacteremia

Presenting
symptoms

Dec, deceased; DM, diabetes mellitus; GI, gastrointestinal; HCT, hematopoietic cell transplantation; HSM, hepatosplenomegaly; ITP, idiopathic thrombocytopenia; MMURD, mismatched unrelated donor; MRD, matched related donor; RBC, red blood cell.

5y
20 y

16 y
27 y

P5

P4

1y
Dec 4 y

P2

19 y

15 y
18 y

P1

Age of
onset/
current

Table 1. Clinical characteristics of male patients with childhood-onset neutropenia
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Figure 1. Patients have mosaic and germline variants in TLR8 with normal expression of TLR8 protein and enhanced responsiveness to TLR8 stimulation. (A) Abdominal
computed tomography scan from P1 showing marked splenomegaly. (B) H&E staining of bone marrow biopsy specimen (P3) showing hypocellularity for age with lymphohistiocytic aggregate (arrow). (C) Leder staining demonstrating myeloid hypoplasia (P3). (D) Family pedigrees of the 6 patients with variants in TLR8. Symbols with dots
indicate mosaicism, and the solid black box indicates a germline variant in P6 (ND, not done). (E) ddPCR of patient DNA showing droplets with TLR8 variant p.P432L (upper left),
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WT/WT

Figure 2. Functional studies demonstrate gain of function of
TLR8. (A) Analysis of residues altered by TLR8 variants show that
positions P432 and F494 contact the symmetric positions in the
other subunit of the active ligand-bound dimer. G572D in the
ligand-binding state is predicted to enter into a hydrophobic
pocket and interact with R375. (B-C) NF-kB reporter cells (HEK
Blue Null1 cells) that do not express endogenous TLR8 were
transfected with WT TLR8, patient TLR8 variants (encoding
p.P432L, p.F494L, p.G572D), or a loss-of-function (LOF) TLR8
variant (encoding p.D543A) and stimulated with the indicated
doses of the TLR8-speciﬁc agonist TL8-506 (B) or the TLR8/TLR7
agonist CLO75 (C) for 24 hours. Mosaic and germline TLR8 variants
lead to gain of function in TLR8 activity as measured by NF-kB
transcriptional activity. Data are represented as mean 6 standard
deviation of biological replicates and representative of 8 independent experiments (TL8-506) or 3 independent experiments
(CLO75). **P # .01, ***P # .001 by 2-way ANOVA test.
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with the same residues from the other subunit (Figure 2A;
supplemental Figure 2A). Similarly, G572, the location of the
germline variant, is solvent exposed in the inactive dimer but is in

close proximity to R375 in the other subunit in the activated
dimer. In both cases, patient amino acid substitutions would be
predicted to kinetically or thermodynamically stabilize activated

Figure 1 (continued) WT TLR8 (lower right), both templates (upper right), or no TLR8 template (lower left) for P1 and the mother. Monos, monocytes; NK, natural killer; WB, whole
blood, NT, no TLR8 template. (F) Percentage of droplets with variant or WT sequence in DNA or cDNA from whole blood or PBMCs, saliva, ﬁbroblast lines, and/or sorted cell
populations. (G) Intracellular TLR8 expression by ﬂow cytometry in cells from age-matched healthy controls (solid red lines) and patients (P1, P3, and P5, solid blue lines). Similar
expression of TLR8 was observed in patient monocytes and neutrophils. CD31 T cells did not express TLR8. Red dashed line and blue dashed line indicates unstained control in
healthy controls and patients respectively. (H) Expression of phosphorylated p65 (NF-kB) in monocytes (CD141) from patients (P1 and P3) and healthy age-matched male controls
stimulated with indicated doses of TLR8 agonist TL8-506. A small percentage (5% to 6%) of patient monocytes responded to the lower dose (100 ng/mL) of the stimulant. Healthy
cells responded at the highest dose of TLR8 stimulation. There was no statistical difference between the patient cells and healthy cells with respect to their response at the
highest dose of stimulation.
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Figure 3. Immunological ﬁndings in TLR8 gain-of-function patients. (A) Representative ﬂow plots of T and B cells immunophenotyping showing a skewed ratio of CD41 T cells
expressing CD45RA or CD45RO (RA:RO ratio) and reduced class-switch memory B cells in a representative patient. (B) Quantitation of CD4:CD8 ratio, CD45RA:CD45RO ratio,
percentage of effector memory T cells re-expressing CD45RA (CD45RA1 CCR72 effector memory T cells [TEMRAs]), and percentage of memory B cells and class-switch memory
B cells relative to age-matched healthy male controls. In contrast to healthy controls, patients had a signiﬁcantly reduced percentage of class-switch memory B cells. Young
healthy male controls (,6 years) are indicated in red and young adult healthy male controls in green. Horizontal line indicates the median; a Mann-Whitney rank sum test was
used for statistical evaluation. Findings that are statistically signiﬁcant are denoted by an asterisk (*P # .05).

TLR8 homodimers through hydrophobic (P432L and F494L) or
charged (G572D) interactions.
A cell line lacking TLR7 and TLR8 (HEK Blue Null1) was transfected with reference (WT) and mutant TLR8 constructs (p.P432L,
p.F494L, and p.G572D), as well as a previously reported loss-offunction mutant, p.D543A15 (supplemental Figure 2C). Overexpression of WT or variant TLR8 did not lead to constitutive
signaling (Figure 2B-C). Following stimulation with the TLR8speciﬁc chemical ligand TL8-506, the 3 putative disease-causing
constructs led to an increased NF-kB activity compared with WT
or loss-of-function constructs (Figure 2B). The gain-of-function
response was independent of the concentration of plasmid
(supplemental Figure 2D) and was also present in the presence
of WT TLR8 (supplemental Figure 2E) and when stimulated with
a TLR8/TLR7 ligand (CLO75) (Figure 2C). When TLR8 variants
were expressed in a reporter cell line also expressing TLR7,
similar enhanced responses to TLR8 ligand, but not TLR7 ligand,
were observed, supporting speciﬁcity of the enhanced responsiveness due to patient variants (supplemental Figure 2F).
Together, these ﬁndings support gain of function of TLR8 due
to the identiﬁed genetic variants.

Immunologic features in patients with
gain-of-function TLR8
Immunologic laboratory features of the patients were variable,
likely due to differences in disease state of patients (Figure 3).
Several patients had evidence of T-cell dysregulation, with inverse CD4:CD8 ratio, skewed naive to memory ratio of CD41
T cells, and elevated CD81 CD45RA1 CCR72 effector memory
T cells . Patients also had increased double-negative T cells
(supplemental Table 2), which is seen in patients with autoimmune lymphoproliferative syndrome but also reﬂective of
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immune dysregulation, autoimmunity, and a lymphoproliferative
state.16,17 Consistent with hypogammaglobulinemia, all patients
had reduced class-switch memory B cells. Further characterization of B-cell subsets in 2 patients identiﬁed reduced frequency of CD24hiCD38hi transitional B cells, CCR61 naive B cells,
and a reduced expression of CD21 on naive B cells relative to
healthy controls (supplemental Figure 3B), suggesting an impairment in activation of naive B cells and maturation of B cells.
One patient had a high percentage of CD21lo/2 B cells (supplemental Figure 3B), a subset of naive B cells that is elevated in
patients with autoimmune diseases and common variable immune deﬁciency, and is associated with splenomegaly and
cytopenias.18-20 Serum cytokine analysis revealed signiﬁcantly
elevated levels of proinﬂammatory cytokines IL-18, IFN-g, IL12/
23p40, and IL2Ra (Figure 4; supplemental Figure 3A). The B-cell
survival factor BAFF was also elevated in patients, consistent with
the observed defects in mature B cells.21 Three patients had
elevated soluble Fas ligand levels (.200 pg/mL), a biomarker of
lymphoproliferative disorders and a mediator of neutropenia in
chronic idiopathic neutropenia and large granular lymphocytic
leukemia.22-24 Monocyte subset analysis showed a reduced
frequency of nonclassical CD14loCD161 monocytes compared
with age-matched controls (supplemental Figure 3C). TLR8
signaling upregulates type I IFNs.9 While 3 patients with mosaic
variants had an increased IFN signature in their peripheral blood
compared with healthy controls, this was lower than patients with
primary disorders of type I IFN production (supplemental Figure 4), suggesting it may not be the major driver of disease in our
patients.25 Bone marrow samples from P1 and P5 were examined
by mass cytometry for intracellular cytokines and other markers
of inﬂammation, and ﬁndings in P1 correlated with that patient’s highly activated T-cell immune phenotype and hyperinﬂammatory cytokine environment detected in the serum
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Figure 4. Elevated serum cytokines in patients. Patients have increased levels of IL-18, IL-18 binding protein (BP), IFN-g, sCD25, BAFF, and IL12/23p40. No statistical difference
was observed between the levels of Fas ligand in the patient and healthy group; however, 3 patients had elevated levels of Fas ligand (.200 pg/mL). Data are represented as
mean 6 standard deviation; a Mann-Whitney rank sum test was used for statistical evaluation. Multiple samples collected .6 months apart were assayed for P1 and P3. Young
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(supplemental Figures 5-7). Together, these studies demonstrate the presence of an inﬂammatory signal in patients with an
activated T-cell phenotype and defects in B-cell maturation and
suggest the possibility of an inﬂammatory environment in the
bone marrow.

Myeloid differentiation of patient-derived iPSCs
and gene-edited CD341 cells
Skin ﬁbroblast lines from P2 and P3 with either the p.P432L or
p.F494L mosaic defects were reprogrammed into iPSCs that
were then single-cell cloned to generate lines with WT or variant
TLR8. Following multiple ($5) passages, cell lines appeared
clonal based on the presence of WT or variant TLR8 DNA
(supplemental Figure 8A). Hematopoietic precursor cells were
differentiated from patient-derived iPSC lines and cultured with
G-CSF to generate neutrophils (Figure 5A; supplemental
Figure 8B-C). HPCs derived from iPSC-p.P432L had 100%
variant TLR8 DNA allele frequency. Following neutrophil

IMMUNODEFICIENCY WITH TLR8 GAIN OF FUNCTION

differentiation, there was an emergence of a small population
(;30%) of neutrophils with WT TLR8 DNA sequence detected by
both ddPCR and Sanger sequencing, potentially due to outgrowth of previously undetectable WT iPSCs through selective
advantage or somatic reversion. However, it is unclear whether
this WT DNA was efﬁciently transcribed and expressed, since
WT cDNA from the same samples was not detected by PCR
(supplemental Figure 8D-E). Stimulation of iPSC-derived neutrophils from WT or variant TLR8 with a TLR8 ligand demonstrated increased NF-kB signaling in samples with TLR8 variants
compared with neutrophils with WT TLR8, demonstrating gain of
function in primary relevant cells (Figure 5A). Similar ﬁndings
were observed in neutrophils from healthy donor hematopoietic
progenitors (CD341 cells) genetically engineered to express the
p.P432L TLR8 variant (Figure 5B; supplemental Figure 9A-C).
Hematopoietic precursor cells derived from patient P2 iPSCs
were also differentiated into macrophages. Similar to neutrophils, macrophages with variant TLR8 (p.P432L) demonstrated
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Figure 5. Myeloid differentiated cells derived from patient iPSCs and gene-edited CD34s with the TLR8 variants demonstrated increased responsiveness to TLR8
stimulation. (A) Cytospin analysis of cells derived from neutrophil differentiation of WT or p.P432L iPSC clones from patient (P2) and WT or p.F494L iPSC clones from patient (P3)
and their upregulation of phosphorylated p65 (NF-kB) in response to stimulation with the indicated doses of the TLR8-ligand TL8-506. (B) H&E stain of cytospin from cells derived
from neutrophil differentiation of WT and gene-edited (p.P432L) healthy donor human CD341 HPCs and their upregulation of phosphorylated p65 (NF-kB) in response to the
TL8-506. Cells in ﬂow plots are gated on CD451CD66b1 neutrophils. Data are representative of 2 independent experiments. (C) Cytospin analysis of cells derived from
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Overall, these experiments demonstrate that both neutrophils
and macrophages with the TLR8 variant have increased responsiveness to TLR8 stimulation, measured by phosphorylation
of NF-kB and cytokine production. The identiﬁcation of WT DNA
in neutrophils and macrophages, but not CD341 HPCs, derived
from TLR8 variant iPSC clones suggests the possibility of a selective advantage for reversion mutations that may be silenced
based on the lack of expressed cDNA.

Discussion
We report 6 unrelated male patients with an IEI characterized by
neutropenia, infections, lymphoproliferation, B-cell defects, and
in some cases bone marrow failure due to mutations in TLR8, the
X-chromosome gene encoding TLR8, a pattern recognition receptor recognizing single-stranded RNA. Importantly, 5 of the 6
patients were mosaic for TLR8 variants, with 4 patients sharing
the same mosaic variant. Mosaicism was ,30%, suggesting an
X-linked dominant phenotype. Detection of TLR8 variants in
multiple tissues, including skin ﬁbroblasts, suggests that mutational events causing disease likely occurred at a relatively early
stage of embryogenesis and are not limited to the hematopoietic compartment in most patients. There are .430 recognized monogenic disorders associated with immunodeﬁciency.1
While genetic mosaicism in known disease-causing genes has
been detected in patients with IEI through targeted sequencing,7 somatic mutation as a primary mechanism of monogenic IEI
is rare.1 Our discovery suggests that mosaicism should be
considered in disease discovery, which will require new approaches to exome and genome analysis to identify lowfrequency genetic variation.
Single-gene defects in TLR8 have not been previously associated with monogenic human disease. Monogenic loss-of-

function defects in signaling molecules downstream of TLR8
been associated with susceptibility to infection and a clinical
phenotype distinct from our patients, including those in genes
encoding IRAK-4, MyD88, IRF7, and the NF-kB protein
complex.26-29 Loss-of-function variants in the gene encoding
TLR3 lead to an IEI with susceptibility to herpes simplex encephalitis.30 Genetic variants in TLR7 were reported in patients
with severe response to SARS-CoV-2 infection, although whether
these confer altered responses to that or other viruses is unknown.31 Studies of the functional role of TLR8 in the immune
response have been limited in large part due to difference in ligand binding between mouse and human TLR8. Deletion of Tlr8
in the mouse leads to increased TLR7 signaling due to the lack of
inhibition by TLR8, with dendritic cells producing high amounts of
cytokines causing spontaneous autoimmunity, autoantibodies,
splenomegaly, and reduced B-cell numbers, similar to features in
our patients.32 By contrast, transgenic expression of human TLR8
also caused increased cytokine production with hyperinﬂammation, even in mice with few as 20% of blood cells containing the human TLR8 transgene, demonstrating a strong
biological effect of TLR8 signaling.33 Our data suggest that TLR7
signaling is not altered with patient TLR8 gain-of-function variants,
based on similar cytokine responses with a TLR7 agonist in
patient-derived macrophages.
The TLR8 variants here lead to a gain-of-function phenotype with
patient-derived cells exhibiting hypersensitivity to ligand stimulation including increased NF-kB activation and cytokine production. The age of onset ranged from infancy to teenage years.
While one of the patients with early-onset disease had a
germline variant (P6), which could be predicted to lead to more
severe disease than low-level genetic mosaicism, patients with
mosaic disease presented between 1 and 16 years. Variant TLR8
was present in ﬁbroblasts of 4 of 5 patients with mosaicism,
suggesting that the mutation occurred at an early stage of
development. While it was not possible to test DNA samples of
patients with later-onset disease to determine whether mosaicism changed, analysis of peripheral blood samples from 2
patients at different time points in their disease demonstrated
stable mosaicism (supplemental Figure 9F). The triggers for
disease in patients with somatic TLR8 variants are uncertain, but
variability of onset age in patients with the same genetic variant
and similar levels of mosaicism suggest that environmental
factors, most likely those known to stimulate TLR8, including
pathogenic bacteria, viruses and commensal microbiota, may
inﬂuence clinical severity and initiation of disease. Following
onset of neutropenia, no patients had remission without therapy,
suggesting that once triggered, the inﬂammatory process
driving disease is not easily controlled and is potentially selfperpetuating. One patient (P5) had refractory ITP 11 years prior
to onset of neutropenia. He had a period of disease remission
following his ITP diagnosis; however, once he developed neutropenia, his disease progressed to require HCT. Interestingly,

Figure 5 (continued) macrophage differentiation of WT or p.P432L induced pluripotent stem cell (iPSC) clones from patient (P2) and phosphorylated p65 (NF-kB) in response to
stimulation with the indicated doses of the TLR8-ligand TL8-506. Cells are gated on CD451CD141 macrophages. (D-E) iPSC-derived macrophages with WT or p.P432L TLR8 from
patient (P2) were cultured overnight with the indicated doses of TL8-506 (TLR8 agonist), CL264 (TLR7 agonist), or LPS (TLR4 agonist). (D) Cytokines were measured in the cell
culture supernatant and demonstrate that macrophages with variant TLR8 produced signiﬁcantly more IL-6 and TNF-a with low-dose TLR8 stimulation (TL8-506, 25ng/mL)
compared with cells with WT TLR8. There was no difference in the cytokine response to TLR7 stimulation (CL264), and doses of CL264 ,100 ng/mL did not result in cellular
activation (data not shown). (E) WT and p.P432L macrophages had a similar response to the TLR4 ligand LPS with respect to production of TNF-a and IL-6. NS, no stimulation.
Data are presented as mean 6 SEM and includes data from 3 independent experiments, analyzed by 2-way ANOVA. Findings that are statistically signiﬁcant are denoted by an
asterisk (*P # .05).
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increased NF-kB signaling in response to TLR8 stimulation
(Figure 5C). As with results from neutrophil assays, undifferentiated iPSC-p.P432L and derived CD341 HPCs did not
have detectable WT TLR8 sequence; however, following differentiation into macrophages, there was again an emergence of
a small population (13%) of cells with WT TLR8 DNA that was not
detected in the transcript (supplemental Figure 9E). Macrophages derived from iPSC-p.P432L cells secreted more IL-6 and
TNF-a compared with iPSC-derived cells with WT TLR8 following overnight stimulation with a low dose of TLR8 agonist
(TL8-506, 25 ng/mL; Figure 5D). These cells also produced more
IL-1b and IL-10 (data not shown). Stimulation of iPSC-derived
macrophages with the TLR7 agonist CL264 demonstrated no
differences in cytokine production (Figure 5D), suggesting that
the TLR8 variants here do not alter responses to TLR7. Stimulation of macrophages through a nonendosomal TLR with lipopolysaccharide (LPS) (TLR4 agonist) demonstrated similar
levels of cytokines (Figure 5E).

this ﬁbroblasts from this patient did not carry the TLR8 variant,
suggesting that the mutation may have been limited to the
hematopoietic compartment in this case.

The phenotype of cytopenias and B-cell defects with lymphoproliferation in our patients has clinical overlap with other IEIs,
including autoimmune lymphoproliferative syndrome, deﬁciency of ADA2, and other primary immune regulatory
disorders.36-39 There is also clinical and pathologic overlap between TLR8 gain of function and T-LGL leukemia, including
elevated levels of IL-18 and IFN-g, bone marrow ﬁndings of
follicular hyperplasia, an activated T-cell phenotype, neutropenia,
and progression to marrow failure in some patients.24,40-43 As many
as 80% of T-LGL leukemia patients have neutropenia of uncertain
etiology, with evidence for elevated Fas ligand from activated
T cells mediating apoptosis of neutrophils and direct cytotoxic
effects of activated T cells on immature neutrophils in that
disease.24,40,42 Pathologic overlap in the marrow of patients with
T-LGL leukemia has also been observed with autoimmune lymphoproliferative syndrome.44
The consistent refractory neutropenia with lymphoproliferation
makes TLR8 gain of function a unique entity among IEIs. While
the mechanism of neutropenia in IEI is often attributed to autoimmunity, only a subset of patients here had detectable
antineutrophil antibodies. Interestingly gain-of-function variants
in another X-linked gene, WAS, are associated with X-linked
severe congenital neutropenia due to a defect in myeloid
differentiation.45-47 Differentiation of neutrophils from patientderived iPSCs expressing TLR8 variants suggests there may be
an intrinsic effect of gain-of-function TLR8 on the development
and/or survival of neutrophils, based on the emergence of cells
with WT TLR8 sequence. However, the dominant effect of a small
number of cells clearly demonstrate a more complex phenotype.
We hypothesize that the mechanism of neutropenia in patients
with TLR8 gain of function is multifactorial, potentially including
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Our ﬁndings of 3 novel variants in TLR8 in 6 unrelated patients
provides evidence for a new monogenic TLR8-associated IEI
with neutropenia, infections, lymphoproliferation, B-cell defects,
and in some patients bone marrow failure. We propose naming
this disorder “inﬂammation, neutropenia, bone marrow failure,
and lymphoproliferation caused by TLR8” (INFLTR8). Identiﬁcation of mosaic variants causing disease demonstrates the
importance of considering somatic mutation as a genetic cause
of IEI, especially in molecularly uncharacterized disease. Considering the range of mosaicism detected in our cohort sufﬁcient
to cause disease (5% to 30%), it is likely that patients with a low
percentage of mosaicism in a disease-causing gene may be
overlooked by exome or genome sequencing. Treatment of the
patients with TLR8 gain of function has proven challenging, and
this is perhaps related to the multifactorial involvement of myeloid cells, T and B lymphocytes, and a proinﬂammatory environment. Further investigation of the functional consequences
of TLR8 gain of function and identiﬁcation of additional patients
will lead to a better understanding of this new disorder and
provide guidance for evidence-based therapy improving longterm outcome.

Acknowledgments
The authors would like to dedicate this article to Joseph and his family.
The authors also wish to thank Joie Davis and Susan Price for their
contributions toward clinical evaluation and care of patients.
Research support was provided by The Children’s Discovery Institute at
Washington University and St. Louis Children’s Hospital, Center for
Pediatric Immunology and St. Louis Children’s Hospital Foundation, The
Jeffrey Modell Diagnostic and Research Center for Primary Immunodeﬁciencies at St. Louis Children’s Hospital, The Immune Deﬁciency
Foundation, and the Washington University Rheumatic Diseases Research Resource-Based Center through National Institutes of Health,
National Institute of Arthritis and Musculoskeletal and Skin Diseases grant
P30AR073752 (M.A.C.). Support was provided by the Genome Engineering and iPSC Center at Washington University, the Bursky Center for
Human Immunology and Immunotherapy Programs (CHiiPs), and the
Division of Intramural Research, National Institutes of Allergy and Infectious Diseases. Support was provided for the Immunomonitoring
Laboratory and immunoassay service by the Alvin J. Siteman Cancer
Center at Washington University School of Medicine and Barnes-Jewish
Hospital, supported in part by a National Institutes of Health, National
Cancer Institute cancer center support grant P30 CA091842. Research reported in this publication was supported by the Washington
University Institute of Clinical and Translational Sciences grant
UL1TR002345 from the National Center for Advancing Translational
Sciences of the National Institutes of Health. Support was provided by
the Centralized Sequencing Initiative, Division of Intramural Research
(DIR), National Institute of Allergy and Infectious Diseases of the
National Institutes of Health. This project has been funded in part with
federal funds from the National Cancer Institute, National Institutes of
Health, under contracts HHSN261200800001E and 75N910D00024,
task order 75N91019F00131.
The content is solely the responsibility of the authors and does not
necessarily represent the ofﬁcial view of the National Institutes of Health.
The content of this publication does not necessarily reﬂect the views or
policies of the Department of Health and Human Services, nor does
mention of trade names, commercial products, or organizations imply
endorsement by the U.S. Government.

ALURI et al

Downloaded from http://ashpublications.org/blood/article-pdf/137/18/2450/1806942/bloodbld2020009620.pdf by guest on 23 June 2022

TLR8 is primarily expressed in neutrophils and other myeloidderived cells. While the most unifying clinical phenotype of
these patients is neutropenia, the other striking ﬁndings in patients were elevated serum cytokines and skewing of adaptive
immune cell compartments. Patients had an activated T-cell
phenotype and abnormal B-cell maturation, and most patients
required immunoglobulin replacement therapy. While some of
the patients here had an elevated type I transcriptional signature
in their peripheral blood, this was much lower than patients with
type I interferonopathies, and patients with TLR8 gain of function
lack other clinical features of these disorders such as vasculopathy, interstitial lung disease, and central nervous system
disease.34 Two patients developed oligoclonal T-cell populations within their bone marrow, with one patient diagnosed
with T-LGL leukemia. A reduced frequency of transitional B cells,
memory B-cell precursors, and class-switch memory B cells
suggests a defect in both transitioning from the bone marrow
and maturing into memory cells. High levels of serum BAFF, a
B-cell survival and differentiation factor normally used by mature
B cells, further correlated with the ﬁndings of low memory
B cells.35 Together, the immunologic ﬁndings in these patients
suggest cell-extrinsic effects of TLR8 gain of function, which we
hypothesize is due to increased inﬂammatory cytokines, activated T cells, and possibly direct interactions with activated
antigen-presenting cells bearing variant TLR8 in patients.

antineutrophil antibodies; proinﬂammatory cytokines such as
IL-18, TNF-a, and IFN-g impairing neutrophil differentiation; and
direct and indirect effects of activated T cells and monocytes,
including cytotoxicity and soluble Fas ligand.41,48
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